Philadelphia, PA (March 24, 2017) –Oncoceutics, Inc. announces that multiple abstracts from the company and its commercial and academic collaborators will be presented at the 2017 annual meeting of the American Association of Cancer Research (AACR) April 2nd – April 5th in Washington DC.
These 15 abstracts highlight the anti-cancer activity and novel mechanisms of the company’s lead molecule ONC201, as well as several other imipridones, driven by the chemical class’s effects on G-protein coupled receptors.
Additionally, they showcase the strong team of collaborators that are currently developing ONC201 and other members of the imipridone family. Ten different institutions have submitted abstracts including leading academic research centers such as the MD Anderson Cancer Center, Fox Chase Cancer Center, Rutgers Cancer Institute of New Jersey, Weill Cornell Medical College, Queens University Belfast, and the NIH, as well as commercial experts in GPCR analysis such as DiscoverX.
The abstracts have been categorized by topic: ONC201 and dopamine receptors, other imipridones, ONC201 mechanism of action, and ONC201 combinations. Timing and location of the presentations can be found below.
ONC201 and Dopamine Receptors:
Abstract no: 5223
Data/Time: Wednesday, April 5, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 9
The small molecule imipridone ONC201 is active in tumor types with dysregulation of the DRD2 pathway
Abstract no: 2792
Data/Time: Monday, April 3, 1:00 – 5:00 PM
Location: Halls AC, Poster Section 32
Antagonism of D2-like dopamine receptors plays a role in ONC201’s anti-cancer effects
Abstract no: 3213
Data/Time: Tuesday, April 4, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 8
Abstract no: 4294
Data/Time: Tuesday, April 4, 1:00 – 5:00 PM
Location: Halls AC, Poster Section 13
Other Imipridones:
Abstract no: 1155
Data/Time: Monday, April 3, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 4
Abstract no: 4147A
Data/Time: Tuesday, April 4, 1:00 – 5:00 PM
Location: Halls AC, Poster Section 5
Abstract no: 3245
Data/Time: Tuesday, April 4, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 9
Abstract no: 1067
Data/Time: Monday, April 3, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 1
ONC201 Mechanism of action:
Abstract no: 1066
Data/Time: Monday, April 3, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 1
Abstract no: 124
Data/Time: Sunday, April 2, 1:00 – 5:00 PM
Location: Halls AC, Poster Section 5
ONC201 kills breast cancer cells by inhibiting mitochondrial respiration
Abstract no: 1487
Data/Time: Monday, April 3, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 19
Abstract no: 5195
Data/Time: Wednesday, April 5, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 7
ONC201 Combinations:
Abstract no: 2102
Data/Time: Monday, April 3, 1:00 – 5:00 PM
Location: Halls AC, Poster Section 4
Abstract no: 3212
Data/Time: Tuesday, April 4, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 8
Abstract no: 1102
Data/Time: Monday, April 3, 8:00 AM – 12:00 PM
Location: Halls AC, Poster Section 2
About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company recently completed a successful Phase I study in solid tumors and has begun additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies. Oncoceutics and collaborative groups have received more than $7 million in grants over the last two years, including grants from the National Cancer Institute, the U.S. Food and Drug Administration, the Pennsylvania Department of Health, and The Musella Foundation. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center. The company has established a robust intellectual property position, including several issued patents.
Contact Rohinton Tarapore for more information.
